GSA Capital Partners’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.37M | Buy |
17,306
+14,134
| +446% | +$1.06M | 0.09% | 329 |
|
|
2026
Q1 | $238K | Buy |
+3,172
| New | +$250K | 0.01% | 1370 |
|
|
2025
Q4 | – | Sell |
-10,172
| Closed | -$665K | – | 1868 |
|
|
2025
Q3 | $665K | Buy |
+10,172
| New | +$497K | 0.06% | 662 |
|
|
2024
Q3 | – | Sell |
-8,231
| Closed | -$392K | – | 1802 |
|
|
2024
Q2 | $392K | Sell |
8,231
-94
| -1% | -$3.85K | 0.03% | 1115 |
|
|
2024
Q1 | $361K | Sell |
8,325
-3,355
| -29% | -$160K | 0.03% | 1098 |
|
|
2023
Q4 | $591K | Buy |
+11,680
| New | +$559K | 0.05% | 685 |
|
|
2023
Q2 | – | Sell |
-9,422
| Closed | -$337K | – | 1714 |
|
|
2023
Q1 | $337K | Buy |
+9,422
| New | +$354K | 0.03% | 954 |
|
|
2022
Q3 | – | Sell |
-5,475
| Closed | -$203K | – | 1690 |
|
|
2022
Q2 | $203K | Buy |
+5,475
| New | +$206K | 0.03% | 1060 |
|
|
2022
Q1 | – | Sell |
-13,368
| Closed | -$407K | – | 1602 |
|
|
2021
Q4 | $407K | Buy |
+13,368
| New | +$421K | 0.05% | 731 |
|
|
2020
Q4 | – | Sell |
-15,842
| Closed | -$752K | – | 1397 |
|
|
2020
Q3 | $752K | Buy |
+15,842
| New | +$880K | 0.13% | 199 |
|
|
2020
Q1 | – | Sell |
-6,288
| Closed | -$380K | – | 1292 |
|
|
2019
Q4 | $380K | Buy |
+6,288
| New | +$375K | 0.04% | 847 |
|
|
2019
Q3 | – | Sell |
-19,690
| Closed | -$1.26M | – | 1542 |
|
|
2019
Q2 | $1.26M | Buy |
19,690
+4,590
| +30% | +$324K | 0.14% | 146 |
|
|
2019
Q1 | $1.23M | Sell |
15,100
-2,800
| -16% | -$181K | 0.12% | 198 |
|
|
2018
Q4 | $968K | Buy |
+17,900
| New | +$913K | 0.11% | 232 |
|
|
2018
Q3 | – | Sell |
-32,200
| Closed | -$1.34M | – | 1758 |
|
|
2018
Q2 | $1.34M | Sell |
32,200
-23,000
| -42% | -$1.02M | 0.07% | 543 |
|
|
2018
Q1 | $2.43M | Buy |
55,200
+7,107
| +15% | +$361K | 0.13% | 189 |
|
|
2017
Q4 | $2.42M | Buy |
48,093
+24,200
| +101% | +$1.33M | 0.15% | 157 |
|
|
2017
Q3 | $1.21M | Buy |
23,893
+2,348
| +11% | +$123K | 0.08% | 393 |
|
|
2017
Q2 | $1.1M | Buy |
+21,545
| New | +$1M | 0.07% | 489 |
|
|
2017
Q1 | – | Sell |
-11,141
| Closed | -$533K | – | 1862 |
|
|
2016
Q4 | $533K | Buy |
+11,141
| New | +$441K | 0.03% | 947 |
|
|
2015
Q4 | – | Sell |
-70,059
| Closed | -$2.83M | – | 1879 |
|
|
2015
Q3 | $2.83M | Sell |
70,059
-57,353
| -45% | -$2.97M | 0.14% | 134 |
|
|
2015
Q2 | $7.33M | Buy |
127,412
+84,511
| +197% | +$5.37M | 0.28% | 27 |
|
|
2015
Q1 | $2.73M | Buy |
42,901
+38,150
| +803% | +$2.59M | 0.11% | 192 |
|
|
2014
Q4 | $293K | Buy |
+4,751
| New | +$234K | 0.02% | 1276 |
|
|
2014
Q3 | – | Sell |
-26,814
| Closed | -$924K | – | 1818 |
|
|
2014
Q2 | $924K | Sell |
26,814
-51,170
| -66% | -$1.61M | 0.04% | 729 |
|
|
2014
Q1 | $3.37M | Buy |
77,984
+60,478
| +345% | +$2.93M | 0.24% | 76 |
|
|
2013
Q4 | $697K | Sell |
17,506
-352
| -2% | -$12.5K | 0.06% | 582 |
|
|
2013
Q3 | $670K | Buy |
+17,858
| New | +$533K | 0.05% | 593 |
|
Other funds holding IONS
GSA Capital Partners's IONS Position: Q2 2026 in Review
GSA Capital Partners increased its Ionis Pharmaceuticals (IONS) stake by 446% in Q2 2026, buying an estimated $1.06M and bringing the position to 17,306 shares worth $1.37M. The position accounts for 0.09% of the portfolio, ranked #329.
GSA Capital Partners first reported a position in IONS in Q3 2013 and has held it in 28 quarters since. The position peaked at $7.33M in Q2 2015. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.
- GSA Capital Partners held 17,306 shares of Ionis Pharmaceuticals worth $1.37M as of Q2 2026.
- GSA Capital Partners bought 14,134 Ionis Pharmaceuticals shares in Q2 2026, an estimated $1.06M.
- Ionis Pharmaceuticals made up 0.09% of GSA Capital Partners's portfolio in Q2 2026, its #329 holding.
- GSA Capital Partners first reported a position in Ionis Pharmaceuticals in Q3 2013 and has held it in 28 quarters since.
- GSA Capital Partners's Ionis Pharmaceuticals position peaked at $7.33M in Q2 2015.
- 515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.
Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.